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Abstract
Introduction: Isotonic crystalloids play a central role in perioperative fluid management. Isooncotic preparations of
colloids (for example, human albumin or hydroxyethyl starch) remain nearly completely intravascular when infused
to compensate for acute blood losses. Recent data were interpreted to indicate a comparable intravascular volume
effect for crystalloids, challenging the occasionally suggested advantage of using colloids to treat hypovolemia.
General physiological knowledge and clinical experience, however, suggest otherwise.
Methods: In a prospective study, double-tracer blood volume measurements were performed before and after
intended normovolemic hemodilution in ten female adults, simultaneously substituting the three-fold amount of
withdrawn blood with Ringer’s lactate. Any originated deficits were substituted with half the volume of 20%
human albumin, followed by a further assessment of blood volume. To assess significance between the
measurements, repeated measures analysis of variance (ANOVA) according to Fisher were performed. If significant
results were shown, paired t tests (according to Student) for the singular measurements were taken. P < 0.05 was
considered to be significant.
Results: A total of 1,097 ± 285 ml of whole blood were withdrawn (641 ± 155 ml/m2 body surface area) and
simultaneously replaced by 3,430 ± 806 ml of Ringer’s lactate. All patients showed a significant decrease in blood
volume after hemodilution (-459 ± 185 ml; P < 0.05) that did not involve relevant hemodynamical changes, and a
significant increase in interstitial water content (+2,157 ± 606 ml; P < 0.05). The volume effect of Ringer’s lactate
was 17 ± 10%. The infusion of 245 ± 64 ml of 20% human albumin in this situation restored blood volume back to
baseline values, the volume effect being 184 ± 63%.
Conclusions: Substitution of isolated intravascular deficits in cardiopulmonary healthy adults with the three-fold
amount of Ringer’s lactate impedes maintenance of intravascular normovolemia. The main side effect was an
impressive interstitial fluid accumulation, which was partly restored by the intravenous infusion of 20% human
albumin. We recommend to substitute the five-fold amount of crystalloids or to use an isooncotic preparation in
the face of acute bleeding in patients where edema prevention might be advantageous.
Introduction
Fluid homeostasis within the human body is the result
of complex interactions between compartments and bar-
riers and the prerequisite of stable hemodynamics [1].
Severe intravascular hypovolemia is undesirable, being
associated with a decreased cardiac output and leading
to tissue hypoperfusion and organ dysfunction [2,3].
Therefore, perioperative infusion therapy should avoid
these complications by replacing blood and fluid losses
as timely and adequately as possible. However, discus-
sions on the adequate type, composition and amount of
fluids are ongoing [2,4,5]. While replacement of crystal-
loidal extracellular losses, such as urinary output and
insensible perspiration, using isotonic crystalloids seems
rational [2], there are controversial opinions for main-
taining or restoring cardiac preload [6]. Theoretical phy-
siological considerations on vascular barrier properties
may suggest a possible advantage of artificial colloids or
natural proteins: iso-oncotic preparations are believed to
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remain within the intravascular space while crystalloids
should distribute evenly across the whole extracellular
compartment, that is, to 80% interstitially [2]. Surpris-
ingly, a prospective randomized trial on 6,997 critically
ill patients showed no differences in mortality or organ
dysfunction when using either human albumin or crys-
talloids for resuscitation guided by common hemodyna-
mical surrogates [7]. Furthermore, the authors observed
only a slight difference of the total infused amount of
the respective solutions. Despite the fact that these
patients might have had, at least partly, an altered vas-
cular barrier, one important question increasingly arose:
is our historical belief in a superior volume effect of col-
loids in comparison to crystalloids just a physiological
myth that should urgently be adapted to clinical reality?
This study assessed, in the highly standardized setup
of preoperative acute normovolemic hemodilution [8]
combined with repeated direct blood volume assess-
ments, the actual volume effect of an isotonic crystalloid
when applied as a substitute of artificial acute blood loss
in patients. Presumably, the vascular barrier primarily
was sufficient and endothelial and capillary functioning
was normal in our model. We hypothesized a relevant
(> 10%) and significant decrease in blood volume when
using Ringer’s lactate for this indication, the primary
study endpoint being blood volume (ml) after hemodilu-
tion. Beyond that, the capacity of hyperoncotic (20%)
human albumin to recruit interstitially lost fluid for car-
diac preload was investigated.
Materials and methods
The study was approved by the ethics committee of our
institution (Ethikkommission der Medizinischen Fakultät
der Ludwig-Maximilians-Universität München, File
number 022-06). All patients gave written informed con-
sent. A prospectively performed power analysis (for
details see Appendix 1) required a total inclusion of ten
patients. All patients had no cardiovascular or pulmon-
ary dysfunctions (American Society of Anesthesiologists
physical status I to II) and were scheduled for radical
hysterectomy because of a carcinoma of the cervix. All
measurements were performed under general anesthesia
to ensure steady-state conditions and to avoid the
unpleasant procedure of inserting central venous and
arterial catheters into an awake patient.
Anesthesiological procedure
After arrival in the operating theatre, monitoring and a
peripheral canula were applied and 60 ml of whole
blood were withdrawn for preparation of two red cell
volume (RCV) measurements (see below). A thoracic
epidural catheter was inserted; however, local anes-
thetics were only infused after having completed the
study protocol. General anesthesia was induced with
sufentanil, propofol, and cisatracurium, and, after tra-
cheal intubation, maintained via a continuous propofol
infusion and repeated sufentanil injections. Mechanical
ventilation with inspiratory oxygen content of 0.4 was
guided to maintain arterial carbon dioxide partial pres-
sure at approximately 40 mmHg. A second peripheral
canula, a femoral arterial, a central venous and a urine
catheter were inserted. Until the end of the study proce-
dure (see below), no additional intravenous infusions
were applied, except for negligible amounts that were
necessary to inject the intravenous drugs. Continuous
monitoring included electrocardiogram, direct arterial
blood pressure, pulse oximetry, determinations of hema-
tocrit and hemoglobin concentration, and arterial blood
gas analyses.
Study protocol
Following induction of general anesthesia, stable hemo-
dynamics were initiated during a time interval of at least
20 minutes after which the baseline blood volume (BV)
measurement (measurement 1) was performed. After
hemodilution (see Hemodilution procedure) a 30 min-
utes break re-ensured hemodynamical steady-state con-
ditions before the next BV measurement was carried out
(measurement 2). In case blood volume decreased in
comparison to baseline measurement 1, half of the defi-
cit was replaced with 20% human albumin (CSL Behring
GmbH, Marburg, Germany). Plasma volume (PV) was
then reassessed (measurement 3) following a repeated
30-minute break for equilibration. RCV has been shown
to remain unchanged if no transfusion or withdrawal of
red cells occurred [9]. Simultaneous to each measure-
ment, hematocrit and cumulative urine production were
recorded (Figure 1). Norepinephrine was applied intra-
venously throughout the study phase to maintain the
mean arterial blood pressure above 60 mmHg.
Hemodilution procedure
Hemodilution was intended to be normovolemic, that is,
to maintain the intravascular volume state. Blood was
removed at a rate of about 25 to 30 ml/min via the arterial
and the central venous lines and simultaneously replaced
with Ringer’s lactate (B. Braun Melsungen AG, Melsungen,
Germany) at the three-fold amount via peripheral canulas.
According to previous studies on volume effects perform-
ing acute normovolemic hemodilution (ANH) as a model
situation, it was intended to withdraw about 700 ml/m2
body surface area (BSA) of whole blood to simulate signifi-
cant bleeding without falling below a hematocrit of 0.24
[9]. The hemodilution bags were weighed on a precision
scale so that the withdrawn blood volume could be evalu-
ated online. Also, hematocrit was frequently measured to
respect the lower threshold. The infused amount of Ring-
er’s lactate (three-fold the loss) was a practicable
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compromise between the physiological expectations sug-
gesting the five-fold amount and recent suggestions from
literature (1.4-fold) [7].
Direct Measurements
Nonradioactive assessment of blood volume components
PV was determined by diluting indocyanine green (ICG)
using the whole blood method [10-12]. In brief, after
calibration of the PV measurement system, we injected
a bolus of the dye via the central venous line. The target
was calculated by extrapolating the theoretical dilution
of ICG at injection time from several timed measure-
ments. Simultaneously, we measured RCV using sodium
fluorescein-labeled autologous red cells, injecting them
via the central venous line. From the dilution, deter-
mined by flow cytometry, we calculated total body RCV,
according to Lauermann and coworkers [13].
For methodological details see Appendix 2.
Determination of hematocrit
Hematocrit was measured in triplicate without correc-
tion for plasma trapping by centrifugation. In discrimi-
nation to the calculated whole body hematocrit (HKWB,
see below) this value, directly determined in samples
gained from large vessels, will be termed the large vessel
hematocrit (HKLV) in the following.
Further major calculations
An exact value of blood volume results from adding the
directly measured red cell and plasma volumes:
BV (ml) = RCV (ml) + PV (ml) (E1)





weight of full ANH bags − 110g) /1.05g/ml (E2)
Equilibration

















Figure 1 Time frame of study procedures including the three measurements between induction of general anesthesia and start of
surgery.
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with 110 g being the sum of the citrate phosphate
dextrose adenine (CPDA-1) fluid content (70 g) and the
weight of empty ANH bags (40 g). The specific gravity
of blood was assumed to be 1.05 g/ml [14].
The red cell content of ANH bags (RCCbag) was calcu-
lated according to:
RCCbag (ml) = (BCbag (ml) + 70 ml)×HKbag (E3)
The theoretical whole body hematocrit (HKWB)
represents a calculated mean hematocrit throughout
the circulation, calculated from quantified blood com-
ponents:
HKWB = RCV (ml) × BV(ml)−1 (E4)
HKWB is normally slightly lower than large vessel
hematocrit (HKLV) measured in blood samples in clini-
cal routine. This phenomenon is reflected by an Fcell
ratio, normally being smaller than one [15,16]:
Fcell = HKWB ×HKLV−1 (E5)
The reason is most likely the existence of the
endothelial glycocalyx, which binds plasma proteins
to the endothelial surface [17]. This functionally
divides the directly measured total PV into circulating
plasma volume (PVcirc) and a noncirculating part
representing the total volume of the endothelial sur-
face layer (ESL).
PVcirc (ml) = (RCV (ml) × (1−HKLV)) ×HKLV−1 (E6)
ESL (ml) = PV (ml) − PVcirc (ml) (E7)
The presumable cumulative increase in interstitial
water content after ANH (IEANH) and after protein infu-
sion (IEPI) vs. baseline was calculated as follows:
IEANH (ml) = (CI (ml) − BW (ml) −UOANH (ml))
+ (BV1 (ml) − BV2 (ml))
(E8)
CI, crystalloidal infusion; BW, blood withdrawal;
UOANH, urinary output during ANH procedure; BV1,
blood volume before ANH; BV2, blood volume after
ANH
IEPI (ml) = IEANH (ml) − (BV3 (ml) − BV2 (ml))
+PI (ml) −UOPI (ml)
(E9)
BV3, blood volume after protein infusion; PI, protein
infusion; UOPI, urinary output during protein infusion
The initial volume effect of Ringer’s lactate (VErl) and
20% human albumin (VEha), that is, that part remaining
within the vasculature for at least 30 minutes after the
end of hemodilution, including a potential additional
volume recruited from the interstitial space, was calcu-
lated according to:
VErl (%) =(




BV2, blood volume after ANH; BV1, blood volume
before ANH; BW, blood withdrawal; CI, crystalloidal
infusion
VEha (%) =(
(BV3 (ml) − BV2 (ml)) × PI (ml)−1
)
× 100 (E11)
BV3, blood volume after protein infusion; PI, protein
infusion
Statistics
A detailed statistical analysis is attached in Appendix 1.
The power analyses were performed using the free
G*Power software, version 3.1.
All data are presented as mean ± standard deviation
(SD), with n indicating the number of patients. All vari-
ables were tested for normality with the Kolmogorov-
Smirnov test and homoscedasticity (homogeneity of var-
iances) with Levene’s test. For comparison of multiple
measurements, repeated measures analyses of variance
(ANOVA) according to Fisher were performed. If signif-
icant results were shown, paired t tests (according to
Student) for the singular measurements were taken. P <
0.05 was considered to be significant. The statistical
software used to conduct the analyses was SPSS 18
(SPSS Inc., Chicago, IL, USA).
Results
The demographic characteristics of the patients can be
taken from Table 1 (for calculations see Appendix 3).
Measured and calculated variables before (measurement
1) and after (measurement 2) the hemodilution procedure,
as well as after albumin infusion (measurement 3) are
shown in Table 2. During hemodilution 1,097 ± 285 ml of
whole blood (641 ± 155 ml/m2), including 347 ± 99 ml of
Table 1 Patient characteristics (n = 10).
Age (yr) 46 ± 11
Height (cm) 165 ± 4
Weight (kg) 65 ± 14
BSA (m2) 1.71 ± 0.17
BMI (kg × m-2) 23.7 ± 5.1
Values are mean ± standard deviation (SD). BMI, body mass index; BSA, body
surface area (for calculations see Appendix 3).
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red cells, were withdrawn and replaced simultaneously by
3,430 ± 806 ml of Ringer’s lactate. This led to a significant
decrease of the total blood volume by 459 ± 185 ml vs.
baseline, the volume effect of the crystalloidal preparation
being 17 ± 10%. Replacement of this deficit with 245 ± 64
ml of 20% human albumin led to an almost complete
restoration of blood volume, the slight remaining deficit in
comparison to measurement 1 was 25 ± 271 ml. Accord-
ingly, the calculated volume effect was 184 ± 63% for the
hyperoncotic protein solution. While replacing the blood
loss with crystalloids caused a significant increase of tissue
water content, remobilization of this interstitial edema by
hyperoncotic protein infusion was partly possible, but
inter-individually quite inconstant (438 ± 299 ml). The
hemodilution procedure led to a significant decrease in
the total volume of the endothelial surface layer by 240 ±
133 ml, which could not be restored by protein infusion.
The systolic, mean and diastolic arterial blood pres-
sure are graphically outlined in Figure 2. No statistically
significant changes of systolic and mean arterial blood
pressures nor heart rate were observed throughout the
study procedure, the heart rate having been 62 ± 14, 58
± 7 and 55 ± 8 beats per minute (bpm) at measure-
ments 1, 2 and 3, respectively (P > 0.05). Norepinephr-
ine dosage after induction of general anesthesia
(measurement 1) was 0.1 ± 0.1 mg/hour. There were no
significant adjustments until the end of the study proce-
dure. No patient received more than 0.2 mg/hour nore-
pinephrine during any phase of the study. There was no
difference of diastolic blood pressures between measure-
ments 2 and 3 (P > 0.05), while a significant difference
between measurements 1 and 2 was observed (P < 0.05).
Discussion
In this prospective investigation on patients being pri-
marily in a cardiocirculatory steady-state, all participants
were significantly hypovolemic compared to the starting
point after an acute blood loss and simultaneous substi-
tution with the three-fold amount of Ringer’s lactate.
This effect was associated with a significant fluid storage
outside the circulation and a marked reduction of an
important structure concerning vascular barrier func-
tioning. The shift outward by more than 80% of the
infused amount of crystalloid was completed within 30
minutes after the end of the hemodilution, being much
faster than generally assumed.
Normovolemic hemodilution is a well established
blood conservation technique, reducing the requirement
for allogeneic red cell transfusions [8]. Autologous
blood is safely stored outside the circulation prior to
elective surgery and retransfused if required. During
withdrawal, the whole blood is replaced simultaneously
by an artificial solution in order to maintain the quanti-
tative component of cardiac preload [18]. From a scien-
tific point of view, this preoperative intervention can be
comprised as simulation of accidental bleeding and ther-
apeutical infusion therapy. The intravascular volume
effect of the chosen substitute, that is, that part remain-
ing within the circulation after intravenous infusion,
determines the required amount to establish or maintain
intravascular normovolemia [19]. A volume effect of, for
example, 100% means that substitution of an equal
amount as withdrawn is necessary, whereas an effect of
50% would require double the amount. In the latter
case, the excessive part of the infused amount is
excreted via the kidneys and/or shifted toward the inter-
stitial space [19].
Numerous volume effects of colloids using various
assessment techniques have been published before,
being, except for 4% gelatine, constantly around 100%
(Table 3) [11,20-26]. As to be expected, only hypertonic
preparations showed an increase of the intravascular
Table 2 Measured and calculated variables (n = 10).
Measurement 1 Measurement 2 Measurement 3
(Before hemodilution) (After hemodilution) (After protein infusion)
RCV (ml) 1,273 ± 249¶ 947 ± 195§ 947 ± 195*
PV (ml) 2,686 ± 297║ 2,554 ± 378║ 2,987 ± 408‡
BV (ml) 3,959 ± 387¶ 3,501 ± 499‡ 3,934 ± 500¶
HKWB 0.32 ± 0.05‡ 0.27 ± 0.04‡ 0.24 ± 0.04‡
HKLV 0.35 ± 0.04‡ 0.28 ± 0.04‡ 0.25 ± 0.04‡
Fcell 0.91 ± 0.03‡ 0.97 ± 0.02§ 0.97 ± 0.02§
ESL (ml) 339 ± 130‡ 99 ± 54§ 120 ± 77§
Cumulative urine production# (ml) 635 ± 200† 884 ± 171†
Increase in interstitial water content# (ml) 2,157 ± 606† 1,719 ± 680†
*Not reassessed, but taken from measurement 2 (no further blood withdrawal), #since the beginning of hemodilution procedure (for calculations see Materials
and Methods section), §P < 0.05 vs. measurement 1, ¶P < 0.05 vs. measurement 2, ║P < 0.05 vs. measurement 3, ‡P < 0.05 vs. both other measurements, †P <
0.05 vs. basal and other measurement, respectively. For further details on the statistical analysis see Appendix 1. Values are mean ± standard deviation (SD). BV,
blood volume; ESL, volume of the endothelial surface layer; Fcell, HKWB ×HKLV−1 ; HKLV, large vessel hematocrit; HKWB, whole body hematocrit; PV, plasma volume;
RCV, red cell volume.
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compartment by significantly more than the infused
amount [24,25]. Obviously, they were able to recruit
fluids from the extravascular towards the circulatory
space. Beyond that, especially direct double-tracer mea-
surements that compared overloading a normovolemic
circulation (hypervolemia) to replacement of acute
blood losses have revealed that colloidal volume effects
might not be consistent, but context-sensitive (Figure 3)
[19]. To our knowledge, only two studies have consid-
ered the volume effect of a hypervolemic crystalloidal
bolus, without simultaneous blood withdrawal. Estima-
tions around 20% were based on indirect calculations
involving the large vessel hematocrit measured 60 min-
utes after bolus infusion [23] or after a slow infusion of
one liter over 90 minutes [27]. The intravascular persis-
tence of isotonic crystalloid boluses to substitute an
acute blood loss has repeatedly been assumed to be
much higher [28], but has not been addressed before.
Directly assessing the entire blood volume using a
double-tracer approach, as performed here, is time-,
personal- and equipment-consuming and, therefore, cur-
rently not available for clinical routine. However, recent
physiological insights suggest that it might be the only
reliable approach to answer scientific questions around
volume effects, mainly for methodological reasons. A
healthy vascular endothelium is covered by a microsco-
pical structure consisting of the endothelial glycocalyx
and bound plasma constituents, mainly proteins [17,29].
This so-called endothelial surface layer, a presumably
important structure concerning vascular integrity [29],
represents an exclusion zone for red cells. Accordingly,
the peripherally measured large vessel hematocrit does
not reflect the mean composition of the total blood
volume, but only that of the freely circulating part [10].
The observed reduction of the total volume of the
endothelial surface layer during ANH caused an
Table 3 Volume effects of colloids in literature.
Preparation [%] n Reference
4% Human Albumin 83 9 [20]
5% Human Albumin 99 6 [26]
20% Human Albumin 250 26 [24]
6% HES 130/0.4 98 10 [11]
6% HES 200/0.62 93 9 [20]
6% HES 450/0.7 120 10 [21]
10% HES 200/0.5 109 10 [22]
14% HES 200/0.5 247 6 [25]
6% Dextran 70 79 14 [27]
4% Gelatine 58 10 [23]
































Figure 2 Systolic, mean and diastolic arterial blood pressure at measurements 1, 2 and 3, respectively. *P < 0.05 vs. measurement 1.
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additional decrease in large vessel hematocrit (HKLV)
beyond that reflecting a net loss of red cells, simply by
increasing their distribution space. This phenomenon
was most likely not an effect of the applied substance
itself, but of intravascular hypervolemia [12]. Obviously,
even the short-term effect preceding the distribution of
Ringer’s lactate over the entire extracellular compart-
ment appears enough to cause these significant altera-
tions at the endothelial surface, leading to an
overestimation of the volume effect when based on
blood volume calculations using hematocrit.
Showing an intravascular volume effect for Ringer’s
lactate of 17 ± 10% while replacing an acute blood loss,
the present data coincide not only with physiological
considerations, but also with clinical observations. It is
interesting to physiologists, but startling to clinicians
that the significant intravascular hypovolemia resulting
from our abortive attempt of normovolemic hemodilu-
tion with crystalloid was not reflected by any clinically
relevant hemodynamical changes or vasopressor require-
ments. This, however, confirms very recent functional
observations in patients before elective surgery [30] and
might be an explanation of what was observed in a
highly cited large prospective clinical trial on a mixed
collective of 6,997 ICU patients [7]. The study compared
resuscitation with isotonic saline vs. an isooncotic
human albumin preparation under routine monitoring
conditions. The patients of the crystalloid group
received in total only the 1.4-fold amount of those stabi-
lized with protein solutions. The interpretation to have
evidence of a similar volume effect between these two
different classes of preparations under intensive care
conditions [7] might be, on the one hand, quite justified,
as critical illness might significantly contribute to a
breakdown of the vascular barrier [29]. On the other
hand, however, the clinical impression of cardiocircula-
tory stability might be put into an interesting new per-
spective by the present data, despite being derived from
a completely different collective under highly standar-
dized conditions: Obviously, at least cardiopulmonary-
compensated patients receiving crystalloids to stabilize
cardiac preload in the face of acute bleeding are endan-
gered to sustain undetected intravascular hypovolemia



















Figure 3 The different volume effects of an isooncotic albumin preparation during volume loading (VL, n = 10) [12] and
normovolemic hemodilution (NH, n = 15) [9] assessed by double-tracer measurements in healthy female patients. *P < 0.05.
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be of relevance to a patient. It has been reported that
compensatory vasoconstriction might negatively influ-
ence local tissue perfusion [31]. Already a blood loss of
10% has been demonstrated to relevantly compromise
splanchnic perfusion [32]. In our study, the mean
decrease in blood volume by 11.6% was most likely
accompanied by an impressive interstitial edema of
more than two liters. This is not only a short-term
effect, but can be relatively lasting and, in addition,
negatively influences microcirculation and tissue oxygen
tension [2]. Even in healthy volunteers, the kidneys need
more than two days to excrete this fluid overload [33].
Postoperative weight gain after fluid overload has been
shown to be associated with an increased perioperative
mortality [34]. Our applied study protocol most likely
created an undesirable patient condition prior to major
abdominal surgery.
By trying to recruit the most likely interstitially accu-
mulated water with a 20% human albumin preparation
we functionally demonstrated a severely impaired bar-
rier competence after hemodilution: The volume effect
of this hyperoncotic preparation was less than half of
the theoretical expectation. Nevertheless, being well
over 100%, hyperoncotic colloids are an option to
recruit interstitially stored fluid toward the circulatory
compartment. It is crucial to bear potential side effects
of hyperoncotic colloids in mind. Whereas a recent
large meta-analysis showed no severe complications for
hyperoncotic preparations of the natural human pro-
tein albumin [35], artificial hyperoncotic solutions are
known to have a negative impact on kidney function
[4]. Further prospective clinical trials on this topic are
urgently needed to clarify the definite role of this class
of preparations.
Conclusion
To maintain or restore blood volume in the face of
acute bleeding, isotonic crystalloids are required in the
five-to-six-fold amount of the estimated deficit to reach
normovolemia, even if the vascular barrier is intact. The
pathophysiological impact of such a volume overload on
the organism might be severe. The actual impact on
outcome after elective surgery, however, or the transfer-
ability of these insights to the critically ill patient remain
unclear and must be urgently investigated in future
studies.
Key messages
• Intravascular volume effect of Ringer’s lactate is
below 20%
• To substitute blood losses with the three-fold
amount of Ringer’s lactate is insufficient and leads to
intravascular hypovolemia
• Intravascular hypovolemia of more than 10%
remained undetected by standard hemodynamical
monitoring (ECG, online arterial blood pressure)
• 20% human albumin might be able to recruit inter-
stitially stored fluid back towards the circulatory
space
Appendix 1
Details on statistical analysis
A) Power analysis
We prospectively performed a power analysis using the
G*Power software, Version 3.1, to estimate the required
sample size. As there were no preliminary data available
on the specific question investigated here, we used the
preoperative blood volume of a comparable collective
published previously (n = 53; 4,123 ± 589 ml). For an
estimated effect size we assumed an ‘occult’ decrease in
blood volume during ANH that was considered to be
relevant, but not yet detectable by hemodynamical
changes (acute blood loss ‘Class I’, that is, 10 to 15% of
the initial blood volume). Due to the high standardiza-
tion of our setup, we assumed similar underlying phy-
siological principles in comparable patients to lead to a
high correlation among the repeated measurements.
This led to the following parameters: predicted effect
size dz = 1.06; a = 0.05; power level (1-b) = 0.90; corre-
lation among repeated measurements r = 0.80. The
required sample size was prospectively calculated to be
ten.
After having investigated ten patients we repeated the
calculation using the true values from our study. A max-
imum power level (1-beta) = 1.0 was shown due to the
high and constant effect of ANH using ringer’s lactate
on blood volume (dz = 2.42) and the correlation among
repeated measurements (r = 0.94).
B) Table 2
RCV: ANOVA: df = 2; F = 91.146; P = 0.000. Paired
tests: measurement 1 vs. measurement 2: df = 9; T =
9.547; P = 0.000; measurement 1 vs. measurement 3: df
= 9; T = 9.547; P = 0.000.
PV: ANOVA: df = 2; F = 17·596; P = 0·000. Paired
tests: measurement 1 vs. measurement 2: n.s.; measure-
ment 1 vs. measurement 3: df = 9; T = -3.150; P =
0.012; measurement 2 vs. measurement 3: df = 9; T =
-7.286; P = 0.000.
BV: ANOVA: df = 2; F = 27.839; P = 0.000. Paired
tests: measurement 1 vs. measurement 2: df = 9; T =
7.832; P = 0.000; measurement 1 vs. measurement 3: n.
s.; measurement 2 vs. measurement 3: df = 9; T =
-7.286; P = 0.000.
HKWB: ANOVA: df = 2; F = 46.221; P = 0.000. Paired
tests: measurement 1 vs. measurement 2: df = 9; T =
5.861; P = 0.000; measurement 1 vs. measurement 3: df
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= 9; T = 7.317; P = 0.000; measurement 2 vs. measure-
ment 3: df = 9; T = 6.708; P = 0.000.
HKLV: ANOVA: df = 2; F = 84.699; P = 0.000. Paired
tests: measurement 1 vs. measurement 2: df = 9; T =
8.56.; P = 0.000; measurement 1 vs. measurement 3: df
= 9; T = 9.795; P = 0.000; measurement 2 vs. measure-
ment 3: df = 9; T = 7.606; P = 0.000.
HKWB/HKLV = Fcell: ANOVA: df = 2; F = 26.191; P =
0.000. Paired tests: measurement 1 vs. measurement 2:
df = 9; T = -6.159; P = 0.000; measurement 1 vs. mea-
surement 3: df = 9; T = -5.841; P = 0.000; measurement
2 vs. measurement 3: n.s.
ESL: ANOVA: df = 2; F = 24.446; P = 0.000. Paired
tests: measurement 1 vs. measurement 2: df = 9; T =
5.725; P = 0.000; measurement 1 vs. measurement 3: df
= 9; T = 5.276; P = 0.001; measurement 2 vs. measure-
ment 3: n.s.
Cumulative urine production: Paired tests: basal vs.
measurement 2: df = 9; T = -10.065; P = 0.000; basal vs.
measurement 3: df = 9; T = -16.389; P = 0.000; mea-
surement 2 vs. measurement 3: df = 9; T = -5.268; P =
0.001.
Increase in interstitial water content: Paired tests:
measurement 1 vs. measurement 2: df = 9; T = -11.261;
P = 0.000; measurement 1 vs. measurement 3: df = 9; T
= -7.996; P = 0.000; measurement 2 vs. measurement 3:
df = 9; T = 4.629; P = 0.001.
C) Results section and Figure 2
Systolic arterial blood pressure: ANOVA: df = 2; F =
1.135; P > 0.05. Paired tests: measurement 1 vs. mea-
surement 2: n.s.; measurement 1 vs. measurement 3: n.
s.; measurement 2 vs. measurement 3: n.s.
Mean arterial blood pressure: ANOVA: df = 2; F =
2.567; P > 0.05. Paired tests: measurement 1 vs. mea-
surement 2: n.s.; measurement 1 vs. measurement 3: n.
s.; measurement 2 vs. measurement 3: n.s.
Diastolic arterial blood pressure: ANOVA: df = 2; F =
4.157; P = 0.027. Paired tests: measurement 1 vs. mea-
surement 2: df = 9; T = 3.278; P = 0.01; measurement 1
vs. measurement 3: n.s.; measurement 2 vs. measure-
ment 3: n.s.
Heart rate: ANOVA: df = 2; F = 1.12; P > 0.05. Paired
tests: measurement 1 vs. measurement 2: n.s.; measure-
ment 1 vs. measurement 3: n.s.; measurement 2 vs. mea-
surement 3: n.s.
Catecholamine requirement: ANOVA: df = 2; F =
2.52; P > 0.05. Paired tests: measurement 1 vs. measure-
ment 2: n.s.; measurement 1 vs. measurement 3: n.s.;
measurement 2 vs. measurement 3: n.s.
As the number of patients was low (n = 10) the size
effect was not checked for in particular, as verification
of statistical significance by itself indicates it to be high
under these conditions.
Appendix 2
Methodological details on double-label blood volume
measurement
A) Determination of plasma volume
Immediately before each central venous dye injection, a
two-point calibration was performed by measuring ali-
quots of the patient’s blood containing two known indo-
cyanine green (ICG) concentrations (ICG-Pulsion,
Pulsion Medical Systems, Munich, Germany). The
extinction of the blood was measured at both 800 and
900 nm in a spectrophotometer developed by our
group. Subtracting extinction at 900 nm from that at
800 nm gives the specific ICG absorption. After calibra-
tion, 0.25 mg/kg of ICG was injected into the central
venous catheter as a bolus dose over five seconds, the
time of injection constituting time point 0. Between the
second and the fifth minute after injection blood was
continuously withdrawn from the arterial catheter
through a cuvette attached to the spectrophotometer
using a calibrated pump (approximately 20 ml/minute),
and immediately reinfused. The ICG concentration at
injection time was derived by monoexponential extrapo-
lation of the curve of 19 extinction values between min-
ute three and including minute five back to zero time.
Measuring points were taken every 10 seconds. If values
right at the beginning of the curve were not log-linear
with respect to the following values, indicating possible
incomplete mixing at these early times, the third minute
was excluded from extrapolation. The criterion was the
R2 value of the initial six extinction values being under
0.99 in the semi-logarithmic plot. Positioning the extra-
polated theoretical absorption value, at injection time,
into the calibration curve yields CB0 - the theoretical
whole-blood concentration of the dye at injection time.
The corresponding theoretical plasma concentration
(CP0) was then calculated as: CP0 = CB0/(1-HKLV),
HKLV being the large vessel hematocrit. The values of
PV were calculated as: PV (ml) = D (mg)/CP0 (mg × ml
-
1), D being the amount of dye injected.
B) Determination of red cell volume
For each measurement, 30 ml of whole blood was taken
from a patient’s peripheral vein to label red blood cells
with sodium fluorescein (Fluorescein-Lösung 10%,
Alcon Pharma, Freiburg, Germany). The blood was cen-
trifuged and the red cell suspension incubated with 48
mg of sodium fluorescein for five minutes. To remove
unbound fluorescein, the cells were washed twice using
a calcium gluconate solution and then resuspended to
the volume of the initial blood sample (30 ml) using
Ringer’s lactate.
The labelled red cells were reinfused via the central
venous catheter. Three samples were drawn from the
arterial catheter between the fifth and the tenth minute
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after injection, stored on ice, and analyzed in the labora-
tory by flow cytometry (FACScan, Becton Dickinson,
Heidelberg, Germany) using an argon laser at 488 nm.
RCV was calculated according to: RCV (ml) = (Ei × Vi
× HKLV)/(Ep × FEf), where Ei = number of red cells
injected per millilitre of labelled cell suspension, Vi =
volume of injected cell suspension (ml), HK = hemato-
crit of the subject’s arterial blood (measured in tripli-
cate), Ep = number of red cells per millilitre in the
patient’s arterial blood (measured in triplicate), and FEf
= fraction of fluorescent erythrocytes as determined by
flow cytometry.
The fraction of fluorescent red cells, determined by
flow cytometry, was the mean value from determina-
tions of all three drawn samples, each counted in tripli-
cate as the number of fluorescent erythrocytes in 50,000
cells. Ei and Ep were obtained using a cell counter (530
nm; Coulter Electronics, Miami, FL, USA).
Appendix 3
Minor calculations from Table 1
Body surface area (BSA) was calculated according to a
formula by Gehan and George [36]: BSA (m2) = 0.0235
× body weight (kg)0.51456 × body height (cm)0.42246.
Body mass index (BMI) was calculated as: BMI (kg ×
m-2) = weight (kg) × (height (m))-2.
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